Avacta, the developer of Affimer biotherapeutics and reagents, has announced that Covance will be presenting Affimer data from a joint study at the European Bioanalysis Forum in Barcelona on 15-17 Nov.

Avacta said Covance will be presenting data that highlights the validation of Affimer as a critical reagent in clinical assays when good batch-to-batch stability and reproducible performance are a regulatory requirement.

It said work carried out collaboratively between Avacta and Covance showed that an Affimer assay to detect and quantify the breast cancer drug Trastuzumab showed good sensitivity and increased assay dynamic range compared to current existing antibody based assays.

At 8:14am: (LON:AVCT) Avacta Group PLC share price was 0p at 67.25p